While the HER2 status of metastases is presumed to be concordant with primary tissue biopsy, 38% (41/108) of a cohort of breast cancer patients with LC and a HER2-negative primary tumor were found to have HER2-positive CTCs in the CSF at our institution [66]. The gene discussed is ERBB2; the disease is breast carcinoma.